MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Phase 1
Completed
Conditions
Obesity
Interventions
First Posted Date
2022-07-06
Last Posted Date
2023-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT05445232
Locations
🇺🇸

Covance Dallas, Dallas, Texas, United States

🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed
Conditions
Non-valvular Atrial Fibrillation
Interventions
First Posted Date
2022-06-30
Last Posted Date
2024-05-20
Lead Sponsor
Pfizer
Target Recruit Count
77814
Registration Number
NCT05438888
Locations
🇯🇵

Pfizer Site, Tokyo, Japan

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

First Posted Date
2022-05-26
Last Posted Date
2022-12-22
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
24
Registration Number
NCT05392127
Locations
🇨🇳

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed
Conditions
Non-valvular Atrial Fibrillation
Interventions
First Posted Date
2022-04-11
Last Posted Date
2024-01-11
Lead Sponsor
Pfizer
Target Recruit Count
193565
Registration Number
NCT05321810
Locations
🇯🇵

Pfizer, Tokyo, Japan

Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

Phase 4
Conditions
Atrial Fibrillation New Onset
Interventions
First Posted Date
2022-03-29
Last Posted Date
2022-03-29
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
50
Registration Number
NCT05300555
Locations
🇧🇷

Heart Institute - University of São Paulo, São paulo, Sao Paulo, Brazil

A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

First Posted Date
2022-03-10
Last Posted Date
2022-12-23
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
22
Registration Number
NCT05273775
Locations
🇨🇳

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Apixaban in Patients With Left Ventricular Thrombus

Phase 3
Completed
Conditions
Left Ventricular Thrombus
Interventions
First Posted Date
2022-01-26
Last Posted Date
2022-01-26
Lead Sponsor
Saud Al Babtain Cardiac Center
Target Recruit Count
50
Registration Number
NCT05208398
Locations
🇸🇦

Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2021-09-16
Last Posted Date
2022-03-10
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
28
Registration Number
NCT05045313
Locations
🇨🇳

First Affiliated Hospital of Soochow University, Suzhou, China

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2021-08-26
Last Posted Date
2023-08-03
Lead Sponsor
Pfizer
Target Recruit Count
55759
Registration Number
NCT05022563
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Sungkyunkwan University, Suwon-si, Korea, Republic of

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

Completed
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
First Posted Date
2021-08-26
Last Posted Date
2023-10-24
Lead Sponsor
Bayer
Target Recruit Count
45000
Registration Number
NCT05022758
Locations
🇰🇷

Many locations, Multiple Locations, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath